Faculty Opinions recommendation of Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS624-TPS624
◽
2021 ◽